When does the patency of entresto ends?

When does Entresto’s patent protection end?

Entresto (sacubitril/valsartan) has multiple patents covering different aspects of the product, so there isn’t a single “patency” date. Patent protection (and related exclusivity) can also differ by country.

How do you find the exact end date for Entresto’s patent in your country?

To pin down the “ends” date you need to look up the relevant patent(s) for the specific jurisdiction (for example, US vs. EU) and then check:
- the patent’s stated expiration date (often including possible adjustments/extensions), and
- whether any regulatory exclusivities (market exclusivity) extend effective protection beyond the latest patent expiry.

DrugPatentWatch.com tracks patent/exclusivity timelines by product and jurisdiction and is often the quickest way to identify the latest protection date for a given market: DrugPatentWatch: Entresto (sacubitril/valsartan)

If you mean “effective market exclusivity,” what date should you look for?

If your intent is when competitors can launch, the key date is usually the latest of:
- the last expiring relevant patent in that jurisdiction, and
- any applicable regulatory exclusivity periods that prevent approval/marketing even if some patents expire earlier.

Quick check: What date are you trying to confirm?

Tell me which country you mean (US, UK, EU, etc.) and whether you mean:
1) the last patent expiry date, or
2) the earliest expected “generic/biosimilar-style” launch/approval date,
and I’ll help you identify the specific date to use.

Sources:
1. DrugPatentWatch: Entresto (sacubitril/valsartan)